Cafergot and Ibu drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Cafergot and Ibu. Common interactions include bronchitis among females and depression among males.

The phase IV clinical study analyzes what interactions people who take Cafergot and Ibu have. It is created by eHealthMe based on reports of 20 people who take Cafergot and Ibu from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.



On Sep, 27, 2022

20 people who take Cafergot and Ibu together, and have interactions are studied.


What is Cafergot?

Cafergot has active ingredients of caffeine; ergotamine tartrate. It is often used in migraine. eHealthMe is studying from 528 Cafergot users for its effectiveness, alternative drugs and more.

What is Ibu?

Ibu has active ingredients of ibuprofen. It is often used in pain. eHealthMe is studying from 211,464 Ibu users for its effectiveness, alternative drugs and more.

Number of Cafergot and Ibu reports submitted per year:

Cafergot and Ibu drug interactions.

Common Cafergot and Ibu drug interactions by gender *:

female:

  1. Bronchitis
  2. Bursitis
  3. Cholecystitis chronic
  4. Cholelithiasis
  5. Cluster headache
  6. Colitis
  7. Diverticulum
  8. Exostosis
  9. Fall
  10. Femur fracture

male:

  1. Depression
  2. Emotional distress
  3. Hypersexuality
  4. Obsessive-compulsive personality disorder
  5. Pathological gambling
  6. Suicidal ideation
  7. Blindness transient

Common Cafergot and Ibu drug interactions by age *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

  1. Angina pectoris
  2. Anxiety
  3. Asthma
  4. Dyspnoea
  5. Palpitations
  6. Sweating increased
  7. Blindness transient
  8. Cardiovascular disorder
  9. Coronary artery disease
  10. Costochondritis

30-39:

n/a

40-49:

  1. Accommodation disorder
  2. Coordination abnormal
  3. Vision blurred

50-59:

  1. Bone metabolism disorder
  2. Breast disorder
  3. Fall
  4. Femur fracture
  5. Gastric polyps
  6. Gastritis
  7. Gastrooesophageal reflux disease
  8. Gingival disorder
  9. Haemorrhagic anaemia
  10. Haemorrhoids

60+:

n/a

Common conditions people have *:

  1. Headache (pain in head): 11 people, 55.00%
  2. Hypersensitivity: 8 people, 40.00%
  3. Osteoporosis (bones weak and more likely to break): 7 people, 35.00%
  4. Osteopenia (a condition where bone mineral density is lower than normal): 7 people, 35.00%
  5. Breast Cancer: 7 people, 35.00%
  6. Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 5 people, 25.00%
  7. Depression: 5 people, 25.00%
  8. High Blood Cholesterol: 5 people, 25.00%
  9. Diabetes: 4 people, 20.00%
  10. Restless Leg Syndrome (a powerful urge to move your legs): 4 people, 20.00%

* Approximation only. Some reports may have incomplete information.

Do you take Cafergot and Ibu?

Personalize this study to your gender and age

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.



Related publications that referenced our studies

Related studies

Alternative drugs to, pros and cons of the 2 drugs:

Common Cafergot and Ibu interactions:

Browse all drug interactions of Cafergot and Ibu:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Ibu interactions:

Browse all interactions between Ibu and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on caffeine; ergotamine tartrate and ibuprofen (the active ingredients of Cafergot and Ibu, respectively), and Cafergot and Ibu (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study. Patients in the study may take other drugs besides Cafergot and Ibu.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: